A Single-Arm, Multicenter, Phase 2 Study of Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2019
At a glance
- Drugs Brigatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Takeda
- 24 Dec 2018 Planned number of patients changed from 80 to 110.
- 31 Aug 2018 Biomarkers information updated
- 29 Jun 2018 Planned End Date changed from 31 May 2021 to 30 Apr 2020.